Analytical Performance of Direct Rapid Nucleic Acid Assay for Detection of SARS-Cov-2

Ozhiparambil Anilkumar Jagan, Mohammed Muhsin Paraparambil Vellamkott, Anzil Bava, Jayalakshmi Anish, Vinaya Acharya, Muhammed Shakir, Seema Oommen

 
International Journal of Biomedicine. 2023;13(4):364-366.
DOI: 10.21103/Article13(4)_ShC2
Originally published December 5, 2023

Abstract: 

Background: A rapid and accurate test to detect SARS-CoV-2 is essential for controlling the transmission of the COVID-19. Rapid diagnostic tests are currently marketed, although it is uncertain how well they perform in actual clinical settings and with relevant subpopulations. We evaluated the clinical performance of the Direct Detect® SARS-CoV-2 Detection Kit (Coyote Bioscience Co., Ltd., Beijing, China) rapid, molecular-based assay.
Methods and Results: The clinical laboratory received 707 clinical samples for rapid PCR between December 2021 and March 2022, including confirmed or suspected COVID-19 cases. These samples were tested by the Direct Detect® SARS-CoV-2 Detection Kit and by the LabGun® COVID-19 ExoFast RT-PCR Kit. Of 707 specimens tested, 649(91.79%) were negative and 58(8.20%) were positive. The sensitivity and specificity of the rapid RT-PCR test were 79.31% (95% CI: 66.65% to 88.83%) and 99.54% (95% CI: 98.66% to 99.90%), respectively.
Conclusion: The Direct Detect® SARS-CoV-2 Detection Kit evaluated in this study was able to detect SARS-CoV-2 infection with high viral loads but not so for higher loads. To determine strategies for appropriate use, more investigation of the assay's field performance in various conditions is required.

Keywords: 
diagnostic testing • SARS-CoV-2 • rapid tests
References: 

1.Tang YW, Schmitz JE, Persing DH, Stratton CW. Laboratory Diagnosis of COVID-19: Current Issues and Challenges. J Clin Microbiol. 2020 May 26;58(6):e00512-20. doi: 10.1128/JCM.00512-20.
2.Mathuria JP, Yadav R, Rajkumar. Laboratory diagnosis of SARS-CoV-2-A review of current methods. J Infect Public Health 2020;13: 901-05. doi: 10.1016/j.jiph.2020.06.005.
3.Woloshin S, Patel N, Kesselheim AS. False Negative Tests for SARS-CoV-2 Infection - Challenges and Implications. N Engl J Med. 2020 Aug 6;383(6):e38. doi: 10.1056/NEJMp2015897.
4.Wang X, Huang Z, Song J, Xiao Y, Wang H. Analytical sensitivity comparison of 14 conventional and three rapid RT-PCR assays for SARS-CoV-2 detection. J Virol Methods. 2021 Jul;293:114144. doi: 10.1016/j.jviromet.2021.114144.
5.U.S. Food and Drug Administration. In Vitro Diagnostics EUAs. Available from: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-em...
6.Drain PK. Rapid diagnostic testing for SARS-CoV-2. N Engl J Med. 2022;386(3):264-72. doi: 10.1056/NEJMcp2117115
7.World Health Organization. Laboratory testing strategy recommendations for COVID-19: Interim guidance, 21 March, 2020. Available from: https://apps.who.int/iris/handle/10665/331509
8.World Health Organization. Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays, September 11th Interim Guidance (2020). Available from: https://www.who.int/publications/i/item/antigen-detection-in-the-diagnos...
9.Platten M, Hoffmann D, Grosser R, Wisplinghoff F, Wisplinghoff H, Wiesmüller G, Schildgen O, Schildgen V. SARS-CoV-2, CT-Values, and Infectivity-Conclusions to Be Drawn from Side Observations. Viruses. 2021 Jul 27;13(8):1459. doi: 10.3390/v13081459.

Download Article
Received September 5, 2023.
Accepted October 25, 2023.
©2023 International Medical Research and Development Corporation.